Business Context and Reporting Period
This Form 8-K Current Report was filed by Senti Biosciences Holdings, Inc. (SNTI) on May 2, 2024, regarding events occurring on April 26, 2024. The filing addresses significant changes in the Company's executive leadership structure, specifically concerning the Chief Financial Officer and Principal Financial Officer roles.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Consulting Fee: $350 per hour for the Interim Chief Financial Officer.
- Maximum Aggregate Payment: $370,000 under the consulting agreement.
Material Changes
The primary material change reported is the appointment of new interim financial leadership effective May 4, 2024:
- Timothy Lu, M.D., Ph.D.: The CEO and President was appointed as Interim Principal Financial Officer and Principal Accounting Officer.
- Yvonne Li: Appointed as Interim Chief Financial Officer. She will assume the duties of Principal Financial Officer and Principal Accounting Officer immediately following the filing of the Form 10-Q for the quarter ended March 31, 2024.
Outlook, Risks, and Unusual Items
The filing notes that the description of the Li Consulting Agreement is not complete and is qualified by reference to the full text, which is expected to be filed as an exhibit to the Form 10-Q for the fiscal quarter ending June 30, 2024. No specific risks, contingencies, or unusual items beyond the leadership transition are detailed in this report.
Investor Verification Checklist
- Verify the exact effective dates for Yvonne Li's assumption of Principal Financial Officer duties relative to the upcoming 10-Q filing.
- Review the full text of the Li Consulting Agreement once filed as an exhibit to the June 30, 2024, 10-Q for complete terms and obligations.
- Monitor future filings for the appointment of a permanent Chief Financial Officer to replace the interim arrangement.